scholarly journals Paradigm-changing osimertinib approval in front-line for advanced NSCLC

2018 ◽  
Vol 16 (6) ◽  
pp. e231-e233
Author(s):  
Jane de Lartigue
Keyword(s):  
Advanced Nsclc ◽  
Front Line

Effects of immediate compared with delayed gefitinib after front-line chemotherapy in Chinese with advanced non-small cell lung cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 8069-8069
Author(s):  
J. Z. Wang ◽  
T. T. An ◽  
L. Yang ◽  
H. Bai ◽  
J. Zhao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Disease Control ◽  
Survival Time ◽  
Egfr Mutation ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Front Line ◽  
Small Cell Lung ◽  
Line Chemotherapy

8069 Background: To compare therapeutic effects of immediate vs. delayed gefitinib used for advanced non-small cell lung cancer (NSCLC) patients who obtained disease control (DC) after front-line chemotherapy in Chinese population. Methods: The study included 121 Chinese with advanced NSCLC treated with standard chemotherapy and obtained DC followed by either immediate gefitinib (66 cases) or delayed gefitinib, i.e. when tumors progressed (55 cases). The disease control rate (DCR), median progression-free survival time (PFS), median overall survival time (OS) of the two groups were analyzed. The impact of EGFR mutation status on the treatments was also evaluated. Results: The median PFS of patients treated in the immediate treatment setting was significantly longer than that of patients without gefitinib treatment (15.23 months versus 8.13 months,P<0.001). However, the overall median PFS was similar in patients treated with either immediate or delayed settings (15.23 months and 16.23 months respectively, P=0.450). There was no significant difference in OS between the two groups. Although patients whose tumors had EGFR mutation showed a longer median PFS compared to those without the mutation in both treatment groups, similar overall PFS was observed between the groups for patients with EGFR mutation (18.75 months and 18.30 months for maintenance and second-line groups, respectively). Conclusions: Immediate gefitinib use may improve PFS for Chinese patients with advanced NSCLC after front-line chemotherapy. However, similar PFS may be achieved by delayed use of gefitinib. No significant financial relationships to disclose.

Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7070-7070 ◽  
Author(s):  
A. A. Adjei ◽  
S. Nair ◽  
N. Reuter ◽  
S. Mandrekar ◽  
S. Kuross ◽  
...  
Keyword(s):  
Phase Ii ◽  
Advanced Nsclc ◽  
Phase Ii Trial ◽  
Front Line ◽  
Line Therapy ◽  
Randomized Phase Ii

Front line chemotherapy in advanced NSCLC with paclitaxel and irinotecan combination

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7127-7127
Author(s):  
G. P. Stathopoulos ◽  
D. Antoniou ◽  
C. Katis ◽  
J. Dimitroulis ◽  
D. Tsavdaridis ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Front Line ◽  
Line Chemotherapy

Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7070-7070 ◽  
Author(s):  
A. A. Adjei ◽  
S. Nair ◽  
N. Reuter ◽  
S. Mandrekar ◽  
S. Kuross ◽  
...  
Keyword(s):  
Phase Ii ◽  
Advanced Nsclc ◽  
Phase Ii Trial ◽  
Front Line ◽  
Line Therapy ◽  
Randomized Phase Ii

Front line chemotherapy in advanced NSCLC with paclitaxel and irinotecan combination

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7127-7127
Author(s):  
G. P. Stathopoulos ◽  
D. Antoniou ◽  
C. Katis ◽  
J. Dimitroulis ◽  
D. Tsavdaridis ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Front Line ◽  
Line Chemotherapy

Platinum-containing regimens as front-line treatment of advanced non-small cell lung cancer in two groups of elderly (≥ 70 year old) patients of different age.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20617-e20617
Author(s):  
Jacopo Giuliani ◽  
Andrea Bonetti ◽  
Anna Mercanti ◽  
Lara Furini ◽  
Emilia Durante ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Advanced Nsclc ◽  
Front Line ◽  
Small Cell Lung ◽  
First Line ◽  
Old Patients ◽  
Group 2 ◽  
Young Old ◽  
Line Chemotherapy ◽  
Group 1

e20617 Background: Elderly patients with advanced Non-Small Cell Lung Cancer (NSCLC) are underrepresented in clinical trials. Therefore we sought to evaluate the impact of a platinum-based doublet, given as a front-line chemotherapy, in two groups of elderly patients of different age with advanced NSCLC. Methods: A retrospective analysis of all consecutives elderly patients ( ≥70 year old) with advanced NSCLC who received a platinum based doublet as front line therapy at our Medical Oncology Unit from February 2005 to September 2011 was performed. The general case study was divided in two groups of patients of different age: “young-old” patients (70-74 year-old) and “old-old” patients (75-81 year-old). Results: Sixty-two consecutive elderly patients with advanced NSCLC were included in this study. Forty patients (65%) were “young-old” patients (group 1, median age 72 years) and 22 (35%) were “old-old” patients (group 2, median age 77 years). Overall, a total of 249 cycles were administered to the 62 patients; 164 cycles were administered to patients in group 1 and 85 cycles were given to patients in group 2; median number of administered cycles per patient was 4 (range 1-6) in both groups. Relevant clincal variables such as sex, stage, ECOG PS, Charlson score and histology were evenly distributed between the two subgroups. Regarding the type of first line chemotherapy, the great majority (92%) was treated with a carboplatin-containing regimen while only five patients (8%) received a cisplatin-based doublet: notably, all these patients are in group 1. Toxicity was mild, with grade 3-4 neutropenia in 17% of group 1 patients and in 9% of group 2 patients. Median OS was 9.8 months in both groups. Conclusions: This retrospective evaluation shows the safety and efficacy of a platinum-based doublet given as first-line chemotherapy in elderly advanced NSCLC patients. For several reasons, including the ease of administration, carboplatin is the preferred platinum analogue. The combination with vinorelbine or gemcitabine is associated with a very good toxicity profile that does not seem to have a detrimental effect on efficacy.

scholarly journals D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC

2007 ◽  
Vol 2 (8) ◽  
pp. S413 ◽  
Author(s):  
Julian R. Molina ◽  
Sumithra J. Mandrekar ◽  
Kendrith Rowland ◽  
Nicholas F. Reuter ◽  
James R. Jett ◽  
...  
Keyword(s):  
Phase Ii ◽  
Mtor Inhibitor ◽  
Advanced Nsclc ◽  
Single Agent ◽  
Window Of Opportunity ◽  
Front Line

scholarly journals Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC

2019 ◽  
Vol 30 ◽  
pp. vi114
Author(s):  
Takayasu Kurata ◽  
Kazuhiko Nakagawa ◽  
Miyako Satouchi ◽  
Takashi Seto ◽  
Takeshi Sawada ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Advanced Nsclc ◽  
Front Line ◽  
Line Therapy

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9016-9016 ◽  
Author(s):  
Shirish M. Gadgeel ◽  
James Stevenson ◽  
Corey J. Langer ◽  
Leena Gandhi ◽  
Hossein Borghaei ◽  
...  
Keyword(s):  
Advanced Nsclc ◽  
Front Line ◽  
Line Therapy

Business: Conceptualizations of Organizational Change Viewed Through the Lens of Power: A Tutorial for the Speech-Language Pathologist/Audiologist Administrator

2011 ◽  
Vol 21 (1) ◽  
pp. 9-17
Author(s):  
Patrick R. Walden
Keyword(s):  
Organizational Change ◽  
Health Care Organizations ◽  
Social Power ◽  
Social Systems ◽  
Front Line ◽  
Organization Level ◽  
Speech Language Pathologist ◽  
Constant State ◽  
Theories Of Change ◽  
Or Organization

Both educational and health care organizations are in a constant state of change, whether triggered by national, regional, local, or organization-level policy. The speech-language pathologist/audiologist-administrator who aids in the planning and implementation of these changes, however, may not be familiar with the expansive literature on change in organizations. Further, how organizational change is planned and implemented is likely affected by leaders' and administrators' personal conceptualizations of social power, which may affect how front line clinicians experience organizational change processes. The purpose of this article, therefore, is to introduce the speech-language pathologist/audiologist-administrator to a research-based classification system for theories of change and to review the concept of power in social systems. Two prominent approaches to change in organizations are reviewed and then discussed as they relate to one another as well as to social conceptualizations of power.

Sign in / Sign up

Export Citation Format

Share Document